Reimbursed Care Access in Moldova

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. National legislation (Law No. 382/1999 and the Governmental list of controlled narcotics/psychotropes — Hotărârea nr.79/2006) places fungi‑derived psilocybin and psilocin within the controlled substances framework; possession and use are subject to administrative and criminal sanctions depending on quantity and intent to distribute. #

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. MDMA is included among psychotropic/stupefiant substances controlled by Moldovan law; simple possession tends to be treated less severely than trafficking but remains illegal and can incur fines or criminal prosecution for larger quantities or distribution. # #

No publicly available evidence of a marketing authorisation, national reimbursement listing, or a formal Spravato/esketamine programme in the Republic of Moldova as of current regulatory registries and agency information. The national regulator for medicines and medical devices, AMDM (Agenția Medicamentului şi Dispozitivelor Medicale), is responsible for marketing authorisations, registration and pharmacovigilance in Moldova; a lack of an entry for esketamine products in AMDM’s public materials and national medicine catalogues indicates there is no accredited, reimbursed esketamine pathway comparable to jurisdictions where Spravato is specifically authorised and funded. Esketamine therefore is not part of routine reimbursed mental‑health care in Moldova and would only be available if (a) an authorised product were registered by AMDM or (b) it were supplied under an exceptional import/compassionate scheme — neither of which has public documentation. For background on the national regulator and its remit, see the AMDM site. # #

Ketamine is an established, licit medicine in Moldova when used for recognised medical indications such as anesthesia and analgesia and is regulated through the national medicines system under the authority of the Agency of Medicines and Medical Devices (AMDM). The Moldovan medicines regulatory framework (AMDM) administrates market authorisations, importation and clinical‑use oversight; substances with accepted medical uses that appear in national formularies and hospital procurement are handled through AMDM processes and hospital pharmaceutical supply channels. # #.

Public reimbursement and routine outpatient coverage: Moldova operates a mixed public/private healthcare financing model with medicines and in‑hospital treatments subject to central procurement, hospital budgets and any national reimbursement lists that AMDM and the Ministry of Health maintain. Ketamine’s conventional role in anesthesia and acute hospital care means it is procured and supplied through hospital formularies and public hospital budgets (i.e., available in state hospitals for approved anaesthetic/analgesic indications); there is no documented national programme reimbursing ketamine for psychedelic or off‑label psychiatric uses (such as intranasal or sub‑anesthetic infusion therapy for depression) and such uses would be considered off‑label and typically paid out‑of‑pocket or restricted to investigator‑led clinical trials. Clinical governance: use for psychiatric indications would require local hospital approval, ethics committee/clinical‑trial authorisation and AMDM oversight if provided in a trial. # #.

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. DMT and its preparations (including ayahuasca blends where DMT is the psychoactive constituent) fall under Moldova’s controlled‑substances lists and are not part of reimbursed medical care. Possession may be subject to administrative fines for small quantities or criminal penalties if trafficking/production is alleged. # #

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. Like other synthetic and natural tryptamines, 5‑MeO‑DMT is not authorised for medical prescription or public reimbursement in Moldova. #

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. Ibogaine is not part of the national pharmacopoeia or reimbursed treatment packages and would only be accessible inside an authorised clinical trial (if such a trial were approved). #

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. Preparations containing DMT (ayahuasca/changa) are treated as controlled and are not part of reimbursed care. Importation, possession or use can trigger administrative fines or criminal investigation depending on circumstances. #

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. Mescaline (and peyote/mescaline‑containing cacti insofar as national law covers plant sources) is not authorised or reimbursed for medical use in Moldova. #

Currently classified as a strictly controlled substance under national drug‑scheduling laws, with no authorized medical use outside of approved clinical research. Synthetic phenethylamine psychedelics (the 2C family and analogues) are controlled under Moldova’s psychotropic/stupefiant schedules and carry criminal penalties for manufacture and distribution. #